Scientists Just Edited a Human Embryo Without Cutting Its DNA

In some experiments, they edited both genes simultaneously in the same embryo. Multiplex base editing at the single-letter level, in a human embryo. That's a sentence that would have sounded like science fiction five years ago.

The Delivery Problem (and How They Solved It)

Getting the base editor into an embryo turned out to be tricky. When the team delivered it as RNA (the standard approach in many gene therapies), the embryos arrested early and stopped developing. Not ideal.

The breakthrough came from switching to pre-formed protein delivery at fertilization. That approach let the edited embryos develop normally all the way to the blastocyst stage, roughly five days of development. The team even derived stem cell lines from the edited embryos, confirming that the edits stuck.

Critically, unlike previous experiments using traditional CRISPR scissors on embryos, the base-edited embryos showed no chromosomal abnormalities or large deletions at the targeted sites. Random insertions and deletions were rare. That's a massive improvement over the mess that standard CRISPR-Cas9 tends to create in embryos.

It's Not Perfect (Yet)

Before anyone starts designing their future children, there are real limitations.

Mosaicism remains a stubborn problem. Some embryos ended up as genetic patchworks, where only a fraction of cells carried the intended edit. If you're trying to correct a disease-causing mutation in every cell, getting it in only half of them defeats the purpose.

Off-target edits showed up too, particularly with the HBG guide RNA. The PCSK9 guide was much cleaner, but the inconsistency highlights that guide RNA design still matters enormously. Every guide sequence brings its own risk profile.

Egli himself has been clear: this technology should not be used to create a baby right now. The embryos were research-only, used to study how cells repair the nicks and mismatches that base editors introduce.

The Ghost of He Jiankui

You can't talk about editing human embryos without talking about He Jiankui, the Chinese scientist who shocked the world in 2018 by creating the first gene-edited babies. He used old-school CRISPR-Cas9 to hack at the CCR5 gene, hoping to confer HIV resistance. The results were sloppy: mosaic mutations, unpredictable alleles, outcomes that nobody fully understood. He went to prison for it.

Egli's work is fundamentally different in both technique and intent. Base editing is more precise, avoids double-strand breaks, and produces far fewer unintended mutations. And nobody is implanting these embryos. But the comparison is unavoidable, because each step forward in embryo editing brings the same uncomfortable question closer: When, if ever, should we allow heritable changes to the human genome?

The Ethics Are Getting Louder

Reactions from the scientific community have been measured but tense. R. Alta Charo, a prominent bioethicist, called the work an "exciting development" on the safety front while stressing that it forces society to confront the bigger question of whether embryo editing should ever be permitted. On the other side, David Barrett of the American Society of Gene and Cell Therapy called the work "unfortunate," arguing that "science is not ready for heritable human genome editing."

The regulatory landscape isn't much help. There's no universal binding international treaty banning heritable genome editing, though the Council of Europe's Oviedo Convention prohibits it among its roughly 30 ratifying states. The WHO's expert committee said in 2021 that clinical use shouldn't proceed, and called it "irresponsible" in 2019, but that guidance carries no legal teeth. In practice, regulation is a patchwork: the UK allows embryo research under strict licensing but bans implantation; the US effectively blocks it through funding restrictions and FDA constraints. No country currently green-lights reproductive germline editing.

But "not currently allowed" and "impossible" are very different things.

Why This Matters Beyond the Lab

Base editing isn't just an embryo story. It's already in the clinic for non-heritable therapies. Verve Therapeutics is running Phase 1b trials using base editing to permanently lower cholesterol by targeting (you guessed it) PCSK9 in adult liver cells. Beam Therapeutics dosed its first patient with a base-editing therapy for alpha-1 antitrypsin deficiency in July 2024 and is running early trials in sickle cell disease.

The somatic applications (editing cells that won't pass changes to offspring) are advancing rapidly and relatively uncontroversially. Egli's embryo work shows that the same precision tools now work in the germline context too. The technology is converging. The only question is whether society's ethical frameworks can keep up.

We just watched a single DNA letter get changed in a human embryo without breaking anything. That's extraordinary science. What we do with it next is an extraordinarily human question.

BMS Is Printing Money Right Now. The Clock Is Ticking.

Bristol Myers Squibb just crushed Q2 estimates and hiked its 2026 forecast by billions, thanks to a blood thinner that won't quit and a new drug lineup firing on all cylinders. There's just one problem: the biggest patent cliff in pharma history is about 18 months away.